Forest Takes On Merck, Novartis In Hypertension; Benicar Another Lexapro?
Executive Summary
Forest/Sankyo's Benicar is rivaling Novartis' Diovan in the number of new patient starts in the angiotensin II inhibitor antihypertensive class, Forest President Kenneth Goodman told the Friedman Billings Ramsey growth conference June 2 in New York
You may also be interested in...
Forest Expects Multiple Celexa Generics To Enter Market In January
Forest Labs is not putting any "impediments" in the way of generic applications for the antidepressant Celexa (citalopram), President Kenneth Goodman told the Friedman Billings Ramsey growth conference June 2 in New York
Novartis Launches Hypertension Awareness Program With Support From HHS
Novartis has the support of HHS and the Centers for Medicare & Medicaid Services for its hypertension disease awareness campaign
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011